Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1985 Jul;54(1):42–47. doi: 10.1136/hrt.54.1.42

Milrinone in heart failure. Effects on exercise haemodynamics during short term treatment.

A D Timmis, P Smyth, D E Jewitt
PMCID: PMC481846  PMID: 4015915

Abstract

The effects of milrinone, a new bipyridine inotropic agent, on the haemodynamic responses to treadmill exercise were studied in 12 patients with congestive heart failure. Four weeks' treatment with milrinone 20 mg daily produced an improvement in left ventricular function during exercise as reflected by significant increments in cardiac index and stroke volume index without change in pulmonary capillary wedge pressure. Systemic oxygen consumption, measured at submaximal exercise, also increased suggesting that the drug induced rise in stroke output was associated with improved skeletal muscle perfusion. Maximum exercise capacity increased. Importantly, the beneficial effects of milrinone on exercise haemodynamics and exercise tolerance were sustained throughout the four week treatment period. No drug related side effects occurred. After treatment with milrinone was stopped left ventricular function deteriorated to a level slightly, but significantly, worse than that before treatment. These observations indicate a potentially useful role for milrinone in treating heart failure.

Full text

PDF
42

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alousi A. A., Stankus G. P., Stuart J. C., Walton L. H. Characterization of the cardiotonic effects of milrinone, a new and potent cardiac bipyridine, on isolated tissues from several animal species. J Cardiovasc Pharmacol. 1983 Sep-Oct;5(5):804–811. doi: 10.1097/00005344-198309000-00015. [DOI] [PubMed] [Google Scholar]
  2. Baim D. S., McDowell A. V., Cherniles J., Monrad E. S., Parker J. A., Edelson J., Braunwald E., Grossman W. Evaluation of a new bipyridine inotropic agent--milrinone--in patients with severe congestive heart failure. N Engl J Med. 1983 Sep 29;309(13):748–756. doi: 10.1056/NEJM198309293091302. [DOI] [PubMed] [Google Scholar]
  3. Benge W., Litchfield R. L., Marcus M. L. Exercise capacity in patients with severe left ventricular dysfunction. Circulation. 1980 May;61(5):955–959. doi: 10.1161/01.cir.61.5.955. [DOI] [PubMed] [Google Scholar]
  4. Benotti J. R., Grossman W., Braunwald E., Carabello B. A. Effects of amrinone on myocardial energy metabolism and hemodynamics in patients with severe congestive heart failure due to coronary artery disease. Circulation. 1980 Jul;62(1):28–34. doi: 10.1161/01.cir.62.1.28. [DOI] [PubMed] [Google Scholar]
  5. Colucci W. S., Alexander R. W., Williams G. H., Rude R. E., Holman B. L., Konstam M. A., Wynne J., Mudge G. H., Jr, Braunwald E. Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol. N Engl J Med. 1981 Jul 23;305(4):185–190. doi: 10.1056/NEJM198107233050402. [DOI] [PubMed] [Google Scholar]
  6. DiBianco R., Shabetai R., Silverman B. D., Leier C. V., Benotti J. R. Oral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal study. J Am Coll Cardiol. 1984 Nov;4(5):855–866. doi: 10.1016/s0735-1097(84)80044-3. [DOI] [PubMed] [Google Scholar]
  7. Fleg J. L., Gottlieb S. H., Lakatta E. G. Is digoxin really important in treatment of compensated heart failure? A placebo-controlled crossover study in patients with sinus rhythm. Am J Med. 1982 Aug;73(2):244–250. doi: 10.1016/0002-9343(82)90186-3. [DOI] [PubMed] [Google Scholar]
  8. Franciosa J. A., Cohn J. N. Effect of isosorbide dinitrate on response to submaximal and maximal exercise in patients with congestive heart failure. Am J Cardiol. 1979 May;43(5):1009–1014. doi: 10.1016/0002-9149(79)90368-0. [DOI] [PubMed] [Google Scholar]
  9. Franciosa J. A., Weber K. T., Levine T. B., Kinasewitz G. T., Janicki J. S., West J., Henis M. M., Cohn J. N. Hydralazine in the long-term treatment of chronic heart failure: lack of difference from placebo. Am Heart J. 1982 Sep;104(3):587–594. doi: 10.1016/0002-8703(82)90231-9. [DOI] [PubMed] [Google Scholar]
  10. Franciosa J. A., Ziesche S., Wilen M. Functional capacity of patients with chronic left ventricular failure. Relationship of bicycle exercise performance to clinical and hemodynamic characterization. Am J Med. 1979 Sep;67(3):460–466. doi: 10.1016/0002-9343(79)90794-0. [DOI] [PubMed] [Google Scholar]
  11. Katz A. M. A new inotropic drug: its promise and a caution. N Engl J Med. 1978 Dec 21;299(25):1409–1410. doi: 10.1056/NEJM197812212992508. [DOI] [PubMed] [Google Scholar]
  12. Maskin C. S., Forman R., Klein N. A., Sonnenblick E. H., LeJemtel T. H. Long-term amrinone therapy in patients with severe heart failure: drug-dependent hemodynamic benefits despite progression of disease. Am J Med. 1982 Jan;72(1):113–118. doi: 10.1016/0002-9343(82)90597-6. [DOI] [PubMed] [Google Scholar]
  13. Maskin C. S., Sinoway L., Chadwick B., Sonnenblick E. H., Le Jemtel T. H. Sustained hemodynamic and clinical effects of a new cardiotonic agent, WIN 47203, in patients with severe congestive heart failure. Circulation. 1983 May;67(5):1065–1070. doi: 10.1161/01.cir.67.5.1065. [DOI] [PubMed] [Google Scholar]
  14. Packer M., Meller J., Gorlin R., Herman M. V. Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure. Circulation. 1979 Mar;59(3):531–539. doi: 10.1161/01.cir.59.3.531. [DOI] [PubMed] [Google Scholar]
  15. Roubin G. S., Choong C. Y., Devenish-Meares S., Sadick N. N., Fletcher P. J., Kelly D. T., Harris P. J. Beta-adrenergic stimulation of the failing ventricle: a double-blind, randomized trial of sustained oral therapy with prenalterol. Circulation. 1984 May;69(5):955–962. doi: 10.1161/01.cir.69.5.955. [DOI] [PubMed] [Google Scholar]
  16. Rubin S. A., Chatterjee K., Parmley W. W. Metabolic assessment of exercise in chronic heart failure patients treated with short-term vasodilators. Circulation. 1980 Mar;61(3):543–548. doi: 10.1161/01.cir.61.3.543. [DOI] [PubMed] [Google Scholar]
  17. Sinoway L. S., Maskin C. S., Chadwick B., Forman R., Sonnenblick E. H., Le Jemtel T. H. Long-term therapy with a new cardiotonic agent, WIN 47203: drug-dependent improvement in cardiac performance and progression of the underlying disease. J Am Coll Cardiol. 1983 Aug;2(2):327–331. doi: 10.1016/s0735-1097(83)80170-3. [DOI] [PubMed] [Google Scholar]
  18. Timmis A. D., Smyth P., Kenny J. F., Campbell S., Jewitt D. E. Effects of vasodilator treatment with felodipine on haemodynamic responses to treadmill exercise in congestive heart failure. Br Heart J. 1984 Sep;52(3):314–320. doi: 10.1136/hrt.52.3.314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Timmis A. D., Smyth P., Monaghan M., Walker L., Daly K., McLeod A. A., Jewitt D. E. Milrinone in heart failure. Acute effects on left ventricular systolic function and myocardial metabolism. Br Heart J. 1985 Jul;54(1):36–41. doi: 10.1136/hrt.54.1.36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Wallenstein S., Zucker C. L., Fleiss J. L. Some statistical methods useful in circulation research. Circ Res. 1980 Jul;47(1):1–9. doi: 10.1161/01.res.47.1.1. [DOI] [PubMed] [Google Scholar]
  21. Weber K. T., Kinasewitz G. T., Janicki J. S., Fishman A. P. Oxygen utilization and ventilation during exercise in patients with chronic cardiac failure. Circulation. 1982 Jun;65(6):1213–1223. doi: 10.1161/01.cir.65.6.1213. [DOI] [PubMed] [Google Scholar]
  22. Wilsmhurst P. T., Webb-Peploe M. M. Side effects of amrinone therapy. Br Heart J. 1983 May;49(5):447–451. doi: 10.1136/hrt.49.5.447. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES